Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2021-11-12 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-11-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing a licensing agreement and preliminary evaluation results for a COVID-19 saliva test. It discusses the partnership, regulatory plans (FDA EUA), and preliminary test results but does not contain any financial data, financial statements, or detailed financial performance. It is not a report, transcript, or regulatory filing in the strict sense but rather a corporate announcement about a business development and product evaluation. The document length is 8731 characters, which is substantial but the content is clearly a press release about a partnership and product evaluation, not a financial or regulatory report. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2021-11-08 English
News release - English.pdf
Director's Dealing Classification · 95% confidence The document is a press release announcing the grant of stock options to a director and other individuals under the company's stock option plan. It includes details about the number of options, exercise price, vesting schedule, and expiration. There is no financial data, no detailed report, no regulatory filing form, and no mention of a meeting or voting results. The document is an announcement related to director and executive compensation through stock options, which fits the category of Director's Dealing (DIRS). The document length is short and it is not a report publication announcement or a certification. Therefore, the best classification is DIRS with high confidence.
2021-09-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2021-09-28 English
Interim MD&A - English.pdf
Regulatory Filings
2021-09-28 English
News release - English.pdf
Regulatory Filings
2021-09-23 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.